The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma

Pathology and Oncology Research

Volumn 20, Issue 1, 2014, Pages 107-112

  Krawczyk, Paweł ^a   Nicoś, Marcin ^a,b   Ramlau, Rodryg ^c,d   Powrózek, Tomasz ^a   Wojas Krawczyk, Kamila ^a   Sura, Sylwia ^a   Jarosz, Bozena ^a   Szumiło, Justyna ^a   Warda, Edward ^a   Mazurkiewicz, Tomasz ^a   Sawicki, Marek ^a   Milanowski, Janusz ^a,e  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b POSTGRADUATE SCHOOL OF MOLECULAR MEDICINE   (Poland)

^c Wielkopolska Center of Pulmonology and Thoracosurgery   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Bone metastases; EGFR gene mutations; EGFR tyrosine kinase inhibitors; Lung adenocarcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NAVELBINE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGE; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; EGFR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PATHOGENESIS; SEX DIFFERENCE; SMOKING HABIT;

ADENOCARCINOMA; BONE NEOPLASMS; EXONS; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84896053117     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9667-4     Document Type: Article

References (17)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistic. CA Cancer J Clin 61:69-90
2. Kadara H, Kabbout M, Wistuba II (2011) Pulmonary adenocarcinoma: a renewed entity in 2012. Respirology 17:50-65
3. Kalikaki A, Koutsopoulos A, Trypaki M et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99:923-929
4. Petrelli F, Borgonovo K, Cabiddu M et al (2012) Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13randomized trials. Clin Lung Cancer 13:107-114
5. Italiano A, Vandenbos FB, Otto J et al (2006) Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 17:981-985 (Pubitemid 43778990)
6. Reungwetwattana T, Weroha SJ, Molina JR (2012) Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 13:252-266
7. Sun L, Zhang Q, Luan H et al (2011) Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 30:30-38
8. Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729-736
9. Suva LJ, Washam C, Nicholas RW et al (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7:208-218
10. Theriault RL, Theriault RL (2012) Biology of bone metastases. Cancer Control 19:92-101
11. Badalian G, Barbai T, Raso E et al (2007) Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 13:99-104 (Pubitemid 47204731)
12. Patel LR, Camacho DF, Shiozawa Y et al (2011) Mechanisms of cancer cell metastasis to the bone: a multistepprocess. Future Oncol 7:1285-1297
13. Krawczyk P, Remiszewski W, Czekajska-Chehab E et al (2009) Evident clinical response to erlotinib as third-line treatment in EGFR FISH (+) male smoker patient with adenocarcinoma of lung. Am J Case Rep 10:166-171
14. Kunimasa K, Masuda G, Watanabe N et al (2012) Diffuse metastases of lung adenocarcinoma with EGFR mutation. Intern Med 51:685-686
15. Togashi Y, Masago K, Kubo T et al (2011) Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer 117:819-825
16. Matsumoto S, Takahashi K, Iwakawa R et al (2006) Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119:1491-1494 (Pubitemid 44258830)
17. Furugaki K, Moriya Y, Iwai T (2011) Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis 28:649-659